Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.37 |
| ▸ | MC5R | P33032 | 16/20 | 0.37 |
| ▸ | MC3R | P41968 | 9/20 | 0.37 |
| ▸ | MC1R | Q01726 | 8/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13270912 | 0.98 | MC4R (0.37) | MC4RMC5RMC3RMC1RL3MBTL1 | |
| Iodide SCHEMBL3134388 | 0.76 | CHRNB2 (0.31) | — | |
| SCHEMBL1325197 | 0.76 | MC4R (0.42) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13270737 | 0.74 | CHRNB2 (0.32) | — | |
| SCHEMBL13677292 | 0.72 | MC4R (0.46) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14111012 | 0.71 | MC4R (0.45) | MC4RMC5RMC3RMC1R | |
| SCHEMBL3137708 | 0.70 | CHRM1 (0.41) | MC4RMC5RMC3RMC1RL3MBTL1 | |
| SCHEMBL13676985 | 0.69 | MC4R (0.44) | MC4RMC5RMC3RMC1R | |
| SCHEMBL9250611 | 0.67 | MC4R (0.39) | MC4RMC5RMC3RMC1RL3MBTL1 | |
| SCHEMBL1324396 | 0.66 | EPHX1 (0.50) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1610789-A4 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060194780-A1 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | disclosed |
| EP-1610789-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087159-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194780-A1 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC5R 2/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.